70,258 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 70,258 shares of the company’s stock, valued at approximately $827,000.

Other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in shares of Phathom Pharmaceuticals by 0.8% during the second quarter. JPMorgan Chase & Co. now owns 138,516 shares of the company’s stock worth $1,328,000 after acquiring an additional 1,123 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in Phathom Pharmaceuticals by 39.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,311 shares of the company’s stock worth $41,000 after purchasing an additional 1,216 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Phathom Pharmaceuticals by 9.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,826 shares of the company’s stock worth $152,000 after purchasing an additional 1,364 shares during the period. Jones Financial Companies Lllp increased its holdings in Phathom Pharmaceuticals by 442.6% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,523 shares of the company’s stock worth $30,000 after purchasing an additional 2,058 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Phathom Pharmaceuticals by 58.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,710 shares of the company’s stock valued at $55,000 after purchasing an additional 2,102 shares during the period. Institutional investors own 99.01% of the company’s stock.

Phathom Pharmaceuticals Price Performance

Phathom Pharmaceuticals stock opened at $11.42 on Friday. The company’s 50-day moving average is $14.66 and its 200-day moving average is $13.37. The firm has a market capitalization of $815.62 million, a PE ratio of -2.99 and a beta of 0.51. Phathom Pharmaceuticals, Inc. has a fifty-two week low of $2.21 and a fifty-two week high of $18.31.

Wall Street Analyst Weigh In

PHAT has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research report on Thursday, January 22nd. Raymond James Financial started coverage on Phathom Pharmaceuticals in a research report on Thursday, December 11th. They set a “strong-buy” rating and a $28.00 price target for the company. Barclays assumed coverage on shares of Phathom Pharmaceuticals in a research note on Monday, December 8th. They set an “equal weight” rating and a $16.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Phathom Pharmaceuticals in a research report on Wednesday, January 14th. Finally, Craig Hallum restated a “buy” rating and set a $22.00 target price on shares of Phathom Pharmaceuticals in a report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.71.

Phathom Pharmaceuticals Profile

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.